$XRAY

Q2 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks

Envista (NYSE:NVST) reported Q2 revenue of $730.5M, up 7.1% YoY, beating estimates. Align Technology (NASDAQ:ALGN) reported $1.06B, up 4.3% YoY, missing revenue guidance. Henry Schein (NASDAQ:HSIC) reported $3.46B, up 6.7% YoY, beating estimates. Stocks are down since reporting.

Original reporting
Published Sep 25, 2026, 10:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 26, 2026, 7:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Q2 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks — source image
Decision brief

The 30-second read

$XRAYNeutralLow
01

Why it matters

All data are recaps of earnings already released weeks earlier; no new catalyst is introduced.

02

Market read

The piece offers a comparative overview but adds no new trading insight; relevance is low.

03

What to watch

None; all material factors were already disclosed in the original earnings releases.

Relevance 4/10Novelty 2/10Timing: none

Background

The article compares Q2 results of four dental‑industry companies, noting revenue growth, earnings beats, and subsequent stock moves.

Company-level read

Ticker impact

$XRAYNeutralHigh confidence
Context

The article reviews Dentsply Sirona's Q2 earnings and compares its performance to peers.

Expected impact

Limited, as the numbers are already priced in.

Evidence & confidence

All figures were disclosed weeks earlier; the piece adds no fresh information.

$NVSTNeutralHigh confidence
Context

Envista's Q2 revenue and EPS beat are summarized, noting a 15.9% post‑report stock decline.

Expected impact

Minimal, since the market has already reacted.

Evidence & confidence

Numbers are not new; the article merely restates them.

$ALGNNeutralHigh confidence
Context

Align Technology's Q2 results are described, highlighting a 19.1% stock drop after the report.

Expected impact

Little effect; price move already occurred.

Evidence & confidence

No new data beyond what was released on 2026‑07‑29.

$HSICNeutralHigh confidence
Context

Henry Schein's Q2 revenue beat and modest 1.1% stock decline are outlined.

Expected impact

Negligible, as the market has priced the results.

Evidence & confidence

The article provides no fresh information.

Market effects

Dental equipment sector performance is summarized but no new sector‑wide driver is introduced.

U.S. market impact is limited; the piece is a post‑earnings recap.

Low; the article does not affect broader market themes.

Counterpoint

No contrarian angle is presented; the article is purely descriptive.

Key entities

  • Dentsply Sirona

    Dental equipment manufacturer (XRAY).

  • Envista Holdings

    Dental products company (NVST).

  • Align Technology

    Invisalign maker (ALGN).

  • Henry Schein

    Dental and healthcare distributor (HSIC).

Related articles

$ALGNMed

Align Technology Shares Fall After Evercore ISI Downgrades Stock

Align Technology (ALGN) shares dropped 1.7% in pre-market trading after Evercore ISI downgraded the stock to In Line from Outperform. The company reported Q2 2026 Clear Aligner revenue of $870.9M, with case shipments at 691,800, but Systems and Services revenue declined 10.8%. ALGN guided for Q3 2026 revenue of $1.0B-$1.02B and full-year growth of 3-4%. The stock has fallen 9.4% over the past month.

$ALGNHigh

Why is Align Technology stock sliding 2% today?

Align Technology (ALGN) stock fell 1.7% in pre-market trading after Evercore ISI downgraded it from 'Outperform' to 'In Line'. The company has 10 buy, 5 hold, and 1 sell ratings. ALGN reported mixed Q2 2026 results with record Clear Aligner revenues but a 10.8% drop in Systems and Services revenue. Q3 guidance and full-year outlook disappointed, contributing to a 9.4% decline over the past month. The stock trades below its 52-week high but above its low, with a fair value estimate of $203.07.

$ALGNHighAI 8/10

How Investors May Respond To Align Technology (ALGN) Lower Revenue Guidance

Align Technology (ALGN) reported quarterly earnings exceeding expectations but lowered Q3 revenue guidance. Management cited inflation and delayed elective dental treatments as factors. Analysts forecast 2029 revenues of $4.7B and earnings of $721.2M, with potential upside or downside depending on demand recovery and competition. The company presented at the 2026 Global Healthcare Conference to discuss its strategy and risks.